X

Trial Profile

A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Duvelisib (Primary) ; Ofatumumab
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Sponsors Secura Bio

Most Recent Events

17 Dec 2020 Status changed from recruiting to completed.
27 Aug 2020 This trial has been completed in France, Austria (Date of global end of trial 12 June 2020) and discontinued in Greece.
28 Jul 2020 This trial is completed in UK - MHRA according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com